- Home
- TAL vs LEGN Comparison
TAL vs LEGN Comparison
Compare TAL & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TAL | LEGN |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.9B |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TAL | LEGN |
|---|---|---|
| Price | $11.10 | $18.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $11.15 | ★ $63.08 |
| AVG Volume (30 Days) | ★ 3.5M | 1.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $34.12 | $46.27 |
| Revenue Next Year | $22.50 | $28.77 |
| P/E Ratio | $23.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.50 | $16.24 |
| 52 Week High | $14.66 | $45.30 |
Technical Indicators
Market Signals| Indicator | TAL | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.70 | 49.02 |
| Support Level | $10.67 | $17.46 |
| Resistance Level | $11.61 | $23.68 |
| Average True Range (ATR) | 0.32 | 0.81 |
| MACD | 0.06 | 0.16 |
| Stochastic Oscillator | 91.71 | 47.10 |
Price Performance
Historical ComparisonAbout TAL TAL Education Group
TAL Education Group is a smart learning solutions provider in China. It operates a few business lines including enrichment learning, high school academic tutoring, learning technology, and content solutions. Among those business lines, TAL focuses on enrichment learning and content solutions.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.